We investigated the association of apolipoproteins AI and B in relation to the prevalence of metabolic syndrome in a random sample of cardiovascular disease— free adults from the ATTICA study (1,514 men, aged 18-87 y; 1,528 women, aged 18-89 y). Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria. The prevalence of metabolic syndrome was 25% in men and 15% in women (P < .001). Using the area under the Receiver Operation Characteristic curve, apolipoprotein B/AI was the best diagnostic marker of metabolic syndrome, the optimal discriminating cut-off value of this ratio was 0.72 (sensitivity 74%, specificity 67%), and individuals with apolipoprotein B/AI ratio greater than 0.74 had 3.29 times higher odds of having metabolic syndrome (95% confidence interval: 2.56-4.21) after adjusting for potential confounders.
Davidson M.The Mobile Lipid Clinic. Philadelphia, PA: Lippincot Williams and Wilkins; 2002.
2.
Gotto AM Jr.Lipid and lipoprotein disorders. In: Pearson TA, Criqui MH , Luepker RV, Oberman A, Wilson M, eds. Primer in Preventive Cardiology. Dallas, TX: American Heart Association;1994:107-129.
3.
Wilson PWF , Abbott RD, Castelli WPHigh-density lipoprotein cholesterol and mortality. Arteriosclerosis . 1988;8:737-741.
4.
Executive summary of the third report of the National Cholesterol Educational Program Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001 ;285:19:2486-2497.
5.
Weber M., McNicoll S., Marcil M., et al. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Can J Cardiol. 1997;13:253-260.
6.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the MetS. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation . 2005;112:2735-2752.
7.
Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A.; GREECE-METS Collaborative Group.Prevalence of vascular disease in MetS using 3 proposed definitions. Int J Cardiol. 2007;117:204-210.
8.
Das UNMetS X: an inflammatory condition? Curr Hypertens Rep. 2004;6:66-73.
9.
Thompson A., Danesh J.Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio, and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006;259:481-492.
10.
Sierra-Johnson J., Somers VK, Kuniyoshi FH, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the MetS . Am J Cardiol. 2006;98:1369-1373.
11.
Spence JDLipoprotein(a): involved in events, but not burden of atherosclerotic disease ? Stroke. 2006;37:1350-1351.
12.
Pitsavos C. , Panagiotakos DB, Chrysohoou C., Stefanadis C.Epidemiology of cardiovascular risk factors in Greece: aims, design, and baseline characteristics of the ATTICA study . BMC Public Health. 2003 ;32:9.
13.
Katsouyanni K., Rimm EB, Gnardellis C., Trichopoulos D., Polychronopoulos E., Trichopoulou A.Reproducibility and relative validity of an extensive semiquantitative food frequency questionnaire using dietary records and biochemical markers among Greek schoolteachers. Int J Epidemiol. 1997 ;26:S118-S127.
14.
Panagiotakos DB, Pitsavos C., Stefanadis C.Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis . 2006;16:559-568.
15.
Guangqin MA , Hall WJConfidence bands for receiver operating characteristic curve. Med Decis Making. 1993:13;191-197.
16.
Yusuf S., Hawken S., Ounpuu S., et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
17.
Schmidt C., Fagerberg B., Wikstrand J., Hulthe J.ApoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis . 2006;1:178-185.
18.
Walldius G. , Jungner I., Holme I., Aastveit AH, Kolar W., Steiner E.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001:358:2026-2033.
19.
Lind L., Vessby B., Sundstrom J.The apolipoprotein B/AI ratio and the MetS independently predict risk for myocardial infarction in middle-aged men. Atheroscler Thromb Vasc Biol. 2006;26:406-410.
20.
Wallenfeldt K., Bokemark L., Wikstrand J., Hulthe J., Fagerberg B.Apolipoprotein B/apolipoprotein A-I in relation to the MetS and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke. 2004:35:2248-2252.
21.
Walldius G. , Jungner I.Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets of lipid-modifying therapy . J Int Med. 2004;255; 188-205.
22.
Meisinger C. , Loewel H., Mraz W., et al. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study . Eur Heart J. 2004; 2005;26(3):271-278.
23.
Walldius G. , Jungner I., Holme I., Aastveit AH, Kolar W., Steiner E.High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
24.
Sniderman AD , Marcovina SMApolipoprotein A1 and B. Clin Lab Med. 2006;26:733-750.
25.
Panagiotakos DB, Pitsavos C., Chrysohoou C., et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study . Am Heart J. 2004;147:106-112.
26.
Athyros VG, Ganotakis ES, Elisaf M., Mikhailidis DPThe prevalence of the MetS using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin. 2005;21:1157-1159.
